Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

Better outcomes with haploidentical than matched sibling donors for adult AML patients allo-transplanted in CR with detectable MRD: A study from the global committee and the ALWP of the EBMT.

Blood (2025) 146 (Supplement 1): 1059.

https://doi.org/10.1182/blood-2025-1059

Published: 2025

Journal Articles

An integrative prognostic model for transplant outcomes in myelofibrosis

Blood (2025) 146 (Supplement 1): 912.

https://doi.org/10.1182/blood-2025-912

Published: 2025

Journal Articles

Matched unrelated vs. Haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis – a randomized prospective european trial.

Blood (2025) 146 (Supplement 1): 171.

https://doi.org/10.1182/blood-2025-171

Published: 2025

Journal Articles

Outcomes of 544 patients with t(6;9) Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation: An EBMT Study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP)

Blood (2025) 146 (Supplement 1): 6066.

https://doi.org/10.1182/blood-2025-6066

Published: 2025

Journal Articles

Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP

Blood (2025) 146 (Supplement 1): 6395.

https://doi.org/10.1182/blood-2025-6395

Published: 2025

Journal Articles

Trends in transplantation for patients with myelodysplastic syndrome across recent decades: A registry-based study on behalf of the chronic malignancies working of the EBMT

Blood (2025) 146 (Supplement 1): 375.

https://doi.org/10.1182/blood-2025-375

Published: 2025

Journal Articles

Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome

Krischan Braitsch, Karin Huber, Andrew Berdel, Lydia Kretschmer, Adrian Gottschlich, Tim Lohmann, Kathrin Rieger, Karsten Spiekermann, Thomas Schroeder, Silke Kapp-Schwoerer, Mareike Verbeek, Florian Bassermann, Hartmut Döhner, Tim Sauer, Christoph Röllig, Jan-Henrik Mikesch, Franziska Westendorf, Lars Fransecky, Katharina S. Götze

Blood (2025) 146 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2025-2846

Published: 2025

Journal Articles

Matched sibling donors still provide superior survival outcomes in older patients with AML in second complete remission. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Blood (2025) 146 (Supplement 1): 2528.

https://doi.org/10.1182/blood-2025-2528

Published: 2025

Journal Articles

Allogeneic hematopoietic cell transplantation in TP53-mutated Acute Myeloid Leukemia patients with active disease: A study from the global committee and the acute leukemia working party of the EBMT

Blood (2025) 146 (Supplement 1): 2523.

https://doi.org/10.1182/blood-2025-2523

Published: 2025

Journal Articles

Multicenter Phase II trial of enasidenib as maintenance treatment following allogeneic stem cell transplantation in IDH2-mutated myeloid neoplasms – the IDH2-post-allo-trial (NCT04522895)

Thomas Schroeder, Matthias Stelljes, Edgar Jost, Jan Moritz Middeke, Gesine Bug, Georg-Nikolaus Franke, Udo Holtick, Christof Scheid, Mareike Verbeek, Caroline Pabst, Hans Christian Reinhardt, Johannes Schetelig, Nicolaus Kröger, Nadja Drusenheimer, Christina Rautenberg, Guido Kobbe

Blood (2025) 146 (Supplement 1): 4302.

https://doi.org/10.1182/blood-2025-4302

Published: 2025

Journal Articles

Survey on fertility management and outcomes after cellular therapies, on behalf of the EBMT cellular therapy and immunobiology working party

Blood (2025) 146 (Supplement 1): 130.

https://doi.org/10.1182/blood-2025-130

Published: 2025

Journal Articles

Prognostic analysis of salvage allogeneic HCT in acute leukemia patients relapsing after autologous HCT: a study from the acute leukemia working party of the EBMT

Blood (2025) 146 (Supplement 1): 6041.

https://doi.org/10.1182/blood-2025-6041

Published: 2025

Journal Articles

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Blood (2025) 146 (Supplement 1): 5298.

https://doi.org/10.1182/blood-2025-5298

Published: 2025

Journal Articles

Allo-HCT outcomes for AML patients with NUP98 rearrangements: A study on behalf of the global committee, the ALWP and the PDWP of the EBMT

Blood (2025) 146 (Supplement 1): 4270.

https://doi.org/10.1182/blood-2025-4270

Published: 2025

Journal Articles

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Blood (2025) 145 (26): 3139–3152.

https://doi.org/10.1182/blood.2024027287

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Blood (2024) 144 (Supplement 1): 3554.

https://doi.org/10.1182/blood-2024-204560

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Posttransplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Cardiovascular Comorbidity Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission from Unrelated Donors: A Retrospective Pair-Match Analysis of EBMT ALWP

Jan Vydra, Allain-Thibeault Ferhat, Nicolaus Kröger, Tobias Gedde-Dahl, Matthias Eder, Thomas Schroeder, Urpu Salmenniemi, Gerard Socie, Jakob Passweg, Sr., Ibrahim Yakoub-Agha, Alessandro Rambaldi, Robert Zeiser, Matthias Stelljes, Kristina Carlson, Cristina Castilla-Llorente, Alexandros Spyridonidis, Fabio Ciceri, Mohamad Mohty

Blood (2024) 144 (Supplement 1): 2161.

https://doi.org/10.1182/blood-2024-198999

Published: 2024

Journal Articles

Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Arnon Nagler, Allain-Thibeault Ferhat, Nicolaus Kröger, Matthias Eder, Gerard Socie, Didier Blaise, Thomas Schroeder, Hélène Labussière-Wallet, Johan Maertens, Alessandro Busca, Edouard Forcade, Tobias Gedde-Dahl, Alessandro Rambaldi, Claude-Éric Bulabois, Fabio Ciceri, Mohamad Mohty

Blood (2024) 144 (Supplement 1): 505.

https://doi.org/10.1182/blood-2024-194057

Published: 2024

Journal Articles

Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Blood (2024) 144 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2024-210920

Published: 2024

Journal Articles

Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis

Blood (2024) 144 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2024-193992

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Better outcomes with haploidentical than matched sibling donors for adult AML patients allo-transplanted in CR with detectable MRD: A study from the global committee and the ALWP of the EBMT.

An integrative prognostic model for transplant outcomes in myelofibrosis

Matched unrelated vs. Haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis – a randomized prospective european trial.

Outcomes of 544 patients with t(6;9) Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation: An EBMT Study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP)

Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP

Trends in transplantation for patients with myelodysplastic syndrome across recent decades: A registry-based study on behalf of the chronic malignancies working of the EBMT

Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome

Matched sibling donors still provide superior survival outcomes in older patients with AML in second complete remission. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Allogeneic hematopoietic cell transplantation in TP53-mutated Acute Myeloid Leukemia patients with active disease: A study from the global committee and the acute leukemia working party of the EBMT

Multicenter Phase II trial of enasidenib as maintenance treatment following allogeneic stem cell transplantation in IDH2-mutated myeloid neoplasms – the IDH2-post-allo-trial (NCT04522895)

Survey on fertility management and outcomes after cellular therapies, on behalf of the EBMT cellular therapy and immunobiology working party

Prognostic analysis of salvage allogeneic HCT in acute leukemia patients relapsing after autologous HCT: a study from the acute leukemia working party of the EBMT

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Allo-HCT outcomes for AML patients with NUP98 rearrangements: A study on behalf of the global committee, the ALWP and the PDWP of the EBMT

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only